Objective;To explore the expression of early protein E6 of human papillomavirus type 16 and 18(HPV16/18E6) and signal induced proliferation associated protein 1 (SIPA1) in cervical cancer, and its relationship to clinic-pathology. Methods;The expression of HPV16/18 E6 and SIPA1 were detected in C33A,HT3,SiHa,HeLa and CaSki cell lines,and paraffin embeded cervical cancer tissues from 174 patients and 40 normal cervical tissues by western blot and immunohistochemistry Envision method respectively. The relationship of HPV16/18 E6 and SIPA1 to pelvic lymph node metastasis and the correlation between expression of SIPA1 and HPV16/18 E6 were analyzed. Results: There was negative correlation between SIPA1 and HPV16/18E6 in cervical cancer cell lines. The positive rate of SIPA1 in normal cervical and cervical cancer tissues was 87. 5% and 58. 6% respectively (x2 = 11. 78, P = 0. 001). In patients with or without lymph node metastasis, the positive rate of SIPA1 was 19. 0% and 71. 2% respectively (x2 = 21. 45,P =0. 000). The risk of lymph node metastasis in patients with negative SIPA1 was higher than positive patients (OR=5. 011, P ＜ 0. 01). The positive rate of HPV16/18 E6 in normal cervix and cervical cancer was 30. 0% and 79. 3% respectively (x2 =37.72,P=0. 000), There was significant difference between the cases with or without lymph node metastasis (x2 =11. 31 ,P = 0. 001). The risk of lymph node metastasis in patients with HPV16/18 E6 positive was higher than negative cases (OR= 14. 794, P ＜ 0. 01). There was negative correlation between SIPA1 and HPV16/18 E6 in cervical cancer (r= -0. 249,P＜0. 001). Conclusions: The down regulation of SIPA1 in cervical cancer is associated with human papillomavirus infection and lymph node metastasis. The efficient HPV16/18 E6 can lead to inhibit SIPA1 expression and SIPA1 can be used as a prognostic marker for lymph node metastasis of cervical cancer.%目的:探讨信号诱导增殖相关蛋白1 (SIPA1)和16、18型人乳头瘤病毒E6蛋白(HPV16/18 E6)在宫颈癌中的表达及其与临床病理之间的关系.方法:Western blot检测宫颈癌C33A、HT3、SiHa、HeLa和CaSki细胞株中HPV16/18 E6和SIPA1蛋白表达;免疫组织化学Envi-sion法检测正常宫颈组织(40例)和宫颈癌组织(174例)石蜡标本中HPV16/18 E6和SIPA1蛋白;分析SIPA1和HPV16/18E6相互之间及其与宫颈癌盆腔淋巴结转移之间的关系.结果:宫颈癌细胞系中SIPA1与HPV16/18 E6表达呈负相关.SIPA1在正常宫颈组织和宫颈癌组织中阳性率分别为87.5％和58.6％,差异有高度统计学意义(x2=11.78,P=0.001);SIPA1蛋白在有和无盆腔淋巴结转移时阳性率分别为19.0％和71.2％,差异有高度统计学意义(x2=21.45,P =0.000),且SIPA1阴性者发生淋巴结转移风险高于阳性者(OR=5.011,95％CI 2.311～10.866,P＜0.01).HPV16/18 E6在正常宫颈组织和宫颈癌组织中的阳性率分别为30.0％和79.3％,差异有高度统计学意义(x2 =37.72,P=0.000);HPV16/18 E6在有和无淋巴结转移时阳性率分别为97.6％和73.5％,差异有高度统计学意义(x2=11.31,P=0.001),HPV16/18E6阳性者淋巴结转移风险高于阴性者(OR=14.794,95％CI 1.960～111.634,P＜0.01).宫颈癌组织中SIPA1与HPV16/18 E6蛋白呈负相关(r=-0.249,P＜0.001).结论:SIPA1蛋白表达与HPV感染有关,HPV16/18 E6有抑制SIPA1表达的作用,SIPA1在抑制宫颈癌的淋巴结转移中发挥着重要作用,可作为宫颈癌盆腔淋巴结转移的早期预测因子.
展开▼
